← Back to Search

Immunomodulator

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Phase 2
Waitlist Available
Research Sponsored by AIM ImmunoTech Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the treatment phase

Summary

This trial tests if Ampligen®, given through an IV, can help reduce fatigue in patients who still feel tired after recovering from COVID-19 by adjusting their immune response. Ampligen® has been studied for its potential to modulate the immune system and has been investigated in various conditions, including chronic fatigue syndrome.

Eligible Conditions
  • COVID-19
  • Post-COVID Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 6 and 13
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 6 and 13 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
6-minute walk test
PROMIS® Cognitive Function Score (T-Score)
PROMIS® Fatigue Score (T-Score)
+1 more
Other study objectives
COVID-19-related symptoms
Duration of Hospitalizations
Hospitalizations
+3 more

Side effects data

From 2021 Phase 2 trial • 19 Patients • NCT03403634
73%
Fatigue
73%
Chills
40%
Hot flush
33%
Pyrexia
33%
Decreased appetite
27%
Nausea
20%
Gastrointestinal disorders **Any AE - Maximum Grade Seen Diarrhoea
20%
Headache
13%
Blood alkaline phosphatase increased
13%
Weight decreased
13%
Myalgia
13%
Vomiting
7%
Pleural Effusion
7%
Dehydration
7%
Dyspnoea
7%
Productive cough
7%
Insomnia
7%
Dizziness
7%
Hyperbilirubinemia
7%
Neoplasm (NOS)
7%
Death
7%
Asthenia
7%
Influenza like illness
7%
Mucosal infection
7%
Sinus congestion
7%
Hypotension
7%
Hyperhidrosis
7%
Dyspepsia
7%
Platelet count decreased
7%
Musculoskeletal pain
7%
Infusion related reaction
7%
Aspartate aminotransferase increased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Ampligen / rintatolimodExperimental Treatment1 Intervention
Subjects will receive rintatolimod (intravenous \[IV\]), up to 400 mg twice weekly for 12 weeks.
Group II: Placebo / SalinePlacebo Group1 Intervention
Subjects will receive placebo / normal saline (intravenous \[IV\]), up to 160 mL twice weekly for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rintatolimod
2019
Completed Phase 2
~120

Find a Location

Who is running the clinical trial?

AIM ImmunoTech Inc.Lead Sponsor
14 Previous Clinical Trials
628 Total Patients Enrolled
Amarex Clinical ResearchOTHER
26 Previous Clinical Trials
1,602 Total Patients Enrolled
5 Trials studying COVID-19
161 Patients Enrolled for COVID-19
David R Strayer, MDStudy DirectorAIM ImmunoTech Inc.
6 Previous Clinical Trials
452 Total Patients Enrolled

Media Library

Rintatolimod (Immunomodulator) Clinical Trial Eligibility Overview. Trial Name: NCT05592418 — Phase 2
COVID-19 Research Study Groups: Ampligen / rintatolimod, Placebo / Saline
COVID-19 Clinical Trial 2023: Rintatolimod Highlights & Side Effects. Trial Name: NCT05592418 — Phase 2
Rintatolimod (Immunomodulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05592418 — Phase 2
~33 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top